Sangamo Therapeutics (SGMOQ) Non-Current Deferred Tax Liability (2013 - 2025)

Sangamo Therapeutics' Non-Current Deferred Tax Liability history runs 9 years deep, the most recent figure standing at $15000.0 for Q1 2025.

• On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $15000.0 in Q1 2025; TTM through Mar 2025 was $15000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $28.1 million, down 9.84% from the prior year.
• Non-Current Deferred Tax Liability fell to $15000.0 in Q1 2025 per SGMOQ's latest filing, from $6.4 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $31.2 million in Q4 2021 and bottomed at $15000.0 in Q1 2025.
• The 4-year median for Non-Current Deferred Tax Liability is $6.6 million (2021), against an average of $10.5 million.
• Across the five-year window, Non-Current Deferred Tax Liability soared 334.29% in 2021 and declined 15.45% in 2022, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $31.2 million in 2021, then declined by 9.84% to $28.1 million in 2022, then plunged by 77.35% to $6.4 million in 2023, then sank by 99.76% to $15000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Non-Current Deferred Tax Liability figures stand at $15000.0 (Q1 2025), $6.4 million (Q1 2023), and $28.1 million (Q4 2022).